RxDoctor Payments Data

Alexander McQueen, MD

Family Medicine · Decatur, ALNPI 1194179341

Payments from drug & device makers

$12,852in general payments, 2019–2025

Across 880 payments — averaging $14.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$1K
  • Lilly USA, LLC$1K
  • AstraZeneca$952
  • GSK$892
  • Amarin Pharma, Inc.$834
  • plus $6K from 41 others

What the payments were for

  • Food & beverage$12,77999%
  • Education$731%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,852 in reported general payments places this provider in the 90th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$108,593
Medicare patients
261
Services billed
2,102

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban155$120,156
OzempicSemaglutide90$107,156
TrulicityDulaglutide66$91,395
MounjaroTirzepatide74$89,367
Chlorzoxazone12$81,544
JanuviaSitagliptin Phosphate94$78,443
JardianceEmpagliflozin54$64,331
FarxigaDapagliflozin Propanediol58$56,329
Trelegy ElliptaFluticasone/Umeclidin/Vilanter36$33,088
Janumet XrSitagliptin Phos/Metformin Hcl20$29,539
Diclofenac Potassium25$21,024
Combivent RespimatIpratropium/Albuterol Sulfate28$20,138
EntrestoSacubitril/Valsartan16$17,340
XareltoRivaroxaban15$14,917
Tresiba Flextouch U-200Insulin Degludec20$14,037

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$1,044$180,762140 claims
PfizerEliquis$654$120,156155 claims
MerckJanuvia, Janumet Xr$177$107,982114 claims
Novo NordiskOzempic$2,280$107,15690 claims
Boehringer IngelheimJardiance, Combivent Respimat$356$84,46982 claims
AstraZenecaFarxiga, Breztri Aerosphere$952$62,99269 claims
GSKTrelegy Ellipta$892$33,08836 claims
NovartisEntresto$183$17,34016 claims
Johnson & JohnsonXarelto$341$14,91715 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$65$13,90314 claims
AbbVieLinzess$1,340$11,46515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Decatur

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →